By David Bautz, PhD NASDAQ:XFOR READ THE FULL XFOR RESEARCH REPORT Business Update NDA Accepted for Priority Review; PDUFA Action Date of April 30, 2024 On October 31, 2023, X4 Pharmaceuticals ...

By David Bautz, PhD NASDAQ:XFOR READ THE FULL XFOR RESEARCH REPORT Business Update PDUFA Date of April 30, 2024 for Mavorixafor for the treatment of WHIM Syndrome In the fourth quarter of 2023, X4 ...

Shareholders holding their stock in book-entry or through brokers need not take any action; changes will be automatically reflected post-split. ... Thursday, XFOR closed at $0.1872, down 1%, ...

Explore X4 Pharmaceuticals analyst ratings and price targets (NASDAQ:XFOR) on Benzinga. Stay updated on expert opinions and forecasts for XFOR stock.

Shares of XFOR stock opened at $0.31 on Friday. The stock has a market capitalization of $52.41 million, a P/E ratio of -3.41 and a beta of 0.39. The company has a current ratio of 4.89, a quick ...

Below is Validea's guru fundamental report for X4 PHARMACEUTICALS INC (XFOR). Of the 22 guru strategies we follow, XFOR rates highest using our Quantitative Momentum Investor model based on the ...